Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Advances in echocardiography for cardiac amyloidosis and restrictive cardiomyopathies
Kafil, Tahir S , Canova, Tyler J., Wang, Tom Kai Ming , Klein, Allan L., Canova, Tyler , Klein, Allan L.

Mayo Clinic

Current Opinion in Cardiology | November 14, 2025 | Volume: 41 | Issue: 1 | Pages: 50-59

10.1097/hco.0000000000001263 | PMID 41236415 Get It

Purpose of review Cardiac amyloidosis is an infiltrative cardiomyopathy with characteristic echocardiographic findings. Echocardiography is the initial imaging test to identify restrictive cardiomyopathies, and timely diagnosis is important for treatment and prognosis. This review outlines key echocardiographic “red flags,” structural and functional findings, and emerging diagnostic tools that enhance early recognition and monitoring of cardiac amyloidosis. Recent findings Classic echocardiographic red flags for cardiac amyloidosis include increased ventricular wall thickness, biatrial enlargement, pericardial effusion, and a granular myocardial appearance. Tissue Doppler imaging shows reduced mitral annular velocities, while advanced disease presents with restrictive filling patterns. Global longitudinal strain with apical sparing is a hallmark finding that distinguishes cardiac amyloidosis from other cardiomyopathies. Left atrial strain has been proposed as a prognostic marker for thromboembolism in cardiac amyloidosis. Evidence shows variability in strain measurements across different vendors, which is an important consideration when comparing results between institutions in both research and clinical practice. Echocardiography can be used in conjunction with multimodal imaging techniques in order to monitor disease progression. Summary Echocardiography is the initial diagnostic test of choice and several findings can suggest cardiac amyloidosis. Advances in echocardiographic techniques have enabled earlier detection of cardiac involvement and now play a central role in both diagnosis and ongoing treatment monitoring.
Intraperitoneal metastasis of gastric cancer: new insights on resident macrophages
Yu, Xianzhe , Zhu, Ling‐Ling , Zhu, Lingling, Wang, Leibo

Mayo Clinic

International Journal of Surgery | November 14, 2025 | Volume: 112 | Issue: 2 | Pages: 4547-4562

10.1097/js9.0000000000003944 | PMID 41233166 Get It

Peritoneal metastasis (PM) is a common and lethal complication of gastric cancer (GC), occurring in approximately 50% of patients with advanced disease. It is characterized by a highly immunosuppressive microenvironment and limited response to current systemic therapies, resulting in a median survival of only 3–6 months. The objective of this review was to explore the critical role of resident macrophages within the peritoneal immune microenvironment in the development and progression of GC PM and to discuss their potential as therapeutic targets. Peritoneal resident macrophages (PRMs), particularly the GATA6⁺ large peritoneal macrophages (LPMs), are hijacked by GC cells through metabolic reprogramming, transcriptional regulation, and paracrine signaling. These macrophages adopt a protumor M2-like phenotype, promote immunosuppression through T-cell exclusion and Treg recruitment, facilitate cancer cell adhesion and spheroid formation, and contribute to chemotherapy resistance. Emerging therapeutic strategies, including cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), nanoparticle-mediated macrophage repolarization, CSF-1 R/CCR2 axis inhibition, and chimeric antigen receptor macrophages (CAR-M), show promise in targeting these cells to restore antitumor immunity. In conclusion, resident macrophages are pivotal in shaping the immunosuppressive landscape of GC PM. Targeting these cells represents a promising avenue for novel combination therapies aimed at improving outcomes for patients with GC PM.
Transformable Renal Cancer Targeted Responsive Nanopeptide Probes Effectively Inhibit Renal Cancer Progression and Metastasis by Inhibiting Renal Blood Vessels and Cancer Cells
Kong, Bin , Wu, Xiu‐Hai, Li, Cong , Chen, Meiqun, Liu, Yuwen , Liu, Cunyao, Wang, Xinyue , Chen, Bogong, Zang, Jiahui, Jian, Lingrui, Shen, Jiachen , Yu, Jiaao, Wu, Qiang , Yang, Guang , Wang, Ziqi , Wang, Lu , Wang, Lu , Liu, Pan , Chen, Meiqun, Liu, Cunyao, Liu, Ming

Mayo Clinic

ACS Applied Materials & Interfaces | November 13, 2025 | Volume: 17 | Issue: 47 | Pages: 64232-64243

10.1021/acsami.5c16546 | PMID 41231680 Get It

The Coexistence of Diabetes Mellitus and Low Fecal Elastase Is Associated With Increased Pancreatic Cancer Risk: A Retrospective, Real-world Cohort Study
Ogbu, Chukwuemeka E. , Babajide, Oyedotun , Ezeani, Chukwunonso , Kollu, Lekhya, Okafor, Philip N. , Wang, Yichen , Osagiede, Osayande

Mayo Clinic

Pancreas | November 11, 2025 | Volume: 55 | Issue: 4 | Pages: e352-e358

10.1097/mpa.0000000000002592 | PMID 41217437 Get It

Objectives: Diabetes mellitus and chronic pancreatitis are established risk factors for pancreatic ductal adenocarcinoma (PDAC). The co-occurrence of exocrine and endocrine pancreatic dysfunction may increase the risk of progression to PDAC and could play a role in early detection. We sought to explore this hypothesis by comparing PDAC risk among patients with diabetes mellitus (DM) and low fecal elastase (FE) in a real-world cohort of patients. Materials and Methods: A retrospective cohort study was conducted using the TriNetX research network including adults with continuous follow-up from 2016 to 2023. The cohort was stratified into 4 groups based on the presence or absence of DM, and normal FE (>200 µg/g) or low FE (<200 µg/g). The 4 groups included: (1) low FE and DM, (2) low FE without DM, (3) normal FE and DM, (4) normal FE without DM. Propensity score matching was performed to balance covariates including age, sex, race, comorbidities to allow for a 6-way comparison of PDAC risk between groups. Time-to-event analyses were conducted with Kaplan-Meier curves and Cox proportional hazards models to estimate hazard ratios (HR) and 95% CIs for the primary outcome of PDAC incidence. Results: Of the study cohort, 29,207 had fecal elastase levels. Low FE (<200 µg/g) was observed in 33% (n = 9585) of these patients. After 6-way comparisons, we observed a higher PDAC risk among individuals with both DM and low FE compared with other groups. The highest PDAC risk was observed in patients with both a low FE (<200 µg/g) and DM compared with those with a normal FE and without a history of DM (HR: 3.68; 95% CI, 2.07–6.53; P < 0.001). Sensitivity analysis using a stricter fecal elastase cutoff of <100 µg/g showed a similar finding, with the highest hazard ratio for PDAC among patients with both DM and very low FE levels (HR: 3.07, 95% CI, 1.37–6.91; P = 0.004). Conclusions: The coexistence of low fecal elastase and DM amplifies the risk of pancreatic ductal adenocarcinoma in our cohort of patients. These results suggest that fecal elastase values may be used to enrich the diabetic population for future PDAC risk stratification, though more studies are needed to validate these findings.
TIP-26. A phase II study evaluating the safety, efficacy, and intracranial activity of tarlatamab in recurrent/refractory IDH -mutant gliomas (TARGID)
Wang, Xin , Bennett, Julie, Muniz, Thiago Pimentel , Fat, Mary Jane Lim, Gao, Andrew , Zadeh, Gelareh , Nassiri, Farshad , Chen, Eric X. , Mason, Warren , Bennett, Julie , Tsang, Derek S.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v426-v427

10.1093/neuonc/noaf201.1686 Get It

Abstract Recurrent or refractory IDH-mutant (mt) gliomas represent a population with significant unmet clinical need. The Notch ligand delta-like 3 (DLL3) is a tumor-associated antigen that is highly and homogeneously expressed in IDH-mt gliomas but absent in normal brain tissue, making it an attractive therapeutic target. Tarlatamab is a half-life extended bispecific T-cell engager that targets DLL3 and CD3 to redirect cytotoxic T cells toward DLL3-expressing tumor cells. Given the specific expression of DLL3 in IDH-mt gliomas and promising activity of tarlatamab in other DLL3-positive tumors, this study investigates the safety, efficacy, and intracranial activity of tarlatamab in this patient population. TARGID is an open-label, phase II trial enrolling adult patients with histologically confirmed IDH1 or IDH2-mt astrocytoma or oligodendroglioma following up to two prior lines of systemic therapies. The study comprises two cohorts. Cohort 1 (n=10) includes patients with resectable disease who will receive up to three cycles of tarlatamab prior to surgery; postoperative continuation is permitted. The primary endpoint for this cohort is the change in CD8+ T-cell infiltration in tumor tissue and blood. Cohort 2 (n=34) includes patients with unresectable disease and uses a Simon’s optimal two-stage design (H0: P ≤ 0.1 versus H1: P ≥ 0.25). In the 1st stage, 13 patients will be accrued. If 2 or more responses are observed, 21 additional patients will be enrolled. Tarlatamab is administered intravenously at 10 mg every two weeks, following a 1 mg priming dose on Cycle 1 Day 1. The primary endpoint is objective response rate by RANO 2.0. Exploratory endpoints include DLL3 expression, circulating biomarkers, and immune correlatives. The trial is currently in activation, with first patient enrollment anticipated in Q3 2025. The study is supported by the provision of study drug from Amgen as an investigator-initiated trial.
TMIC-16. A Multi-Omic Approach Reveals Glioblastoma Derived Brain Tumor Initiating Cell Extracellular Vesicles Induce Pro-Tumorigenic Changes on Neural Progenitor Cells of the Tumor Microenvironment
Russo, Marissa , Mukherjee, Shreyartha, Wickland, Daniel P. , Lam, TuKiet T. , Norton, Emily S. , Wang, Weiwei , Mukherjee, Shreyartha, Guerrero‐Cazares, Hugo

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v446-v447

10.1093/neuonc/noaf201.1771 Get It

Abstract Glioblastoma (GBM), the most aggressive primary brain tumor in adults, presents significant challenges due to its universal recurrence and limited survival rates, exacerbated when proximal to the lateral ventricles (LV). The subpopulation of brain tumor-initiating cells (BTICs) plays a pivotal role in tumor initiation and invasiveness, interacting with the microenvironment, particularly the cellular components in the subventricular zone (SVZ), like Neural Progenitor Cells (NPCs). Mechanisms of intercellular communication present in the SVZ include paracrine, autocrine, direct cell contact, and more recently extracellular vesicles (EVs). EVs are membrane-bound particles released by cells that are central to intercellular communication. They carry bioactive proteins, RNA, and other molecules that influence recipient cell behavior. This study investigates the role of EVs in GBM’s communication with non-cancer cells. Our findings indicate that BTIC-derived EVs promote migration and proliferation (*p &lt; 0.02, ****p &lt;0.001) in NPCs in vitro, highlighting the EVs’ role in altering the microenvironment. Additionally, we leverage a multi-omic approach to profile the small RNA and protein cargo of BTIC-EVs while also evaluating changes in the transcriptome of NPCs after BTIC-EV treatment. To identify the protein cargo contained in GBM-derived EVs, we utilized the innovative proximity-labeling system TurboID. We successfully induced TurboID expression in primary-cultured human BTICs from GBM patients, enabling the unbiased biotinylation of proteins in EVs. This method marks the first implementation of TurboID for unbiased global labeling of EV protein cargo in primary GBM cells. We identified unique miRNAs to be regulators of NPC’s transcriptome, and ontogenic analysis revealed upregulation of pathways involved in maintaining stem-like state, and upregulating PI3k-AKT, mTOR, and WNT signaling. This approach facilitates the investigation of EV-mediated communication and potential therapeutic targets, contributing to the understanding of GBM’s complex interactions with the brain’s microenvironment and the identification of biomarkers for improved diagnosis and treatment response.
PTHP-11. Assessment of Molecular Tools in Pediatric, Adolescent and Young Adult Meningioma Highlights Unique Biology and Underscores the Need for Lifespan Precision in Neuro-Oncology
Yefet, Leo, Landry, Alexander , Wang, Justin Z. , Patil, Vikas , Ajisebutu, Andrew, Gui, Chloe , Aldape, Kenneth , Nassiri, Farshad , Zadeh, Gelareh , Yefet, Leo, Liu, Jeff , Ellenbogen, Yosef

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v269-v269

10.1093/neuonc/noaf201.1068 Get It

Abstract Pediatric, adolescent and young adult patients (Ped/AYA; 0–39 years) with meningiomas are underrepresented in neuro-oncology research, despite meningiomas being the second most common primary brain tumor in this age group. While DNA methylation-based models have advanced classification and prognostication in adults, their utility in younger populations remains uncertain. To address this gap, we aimed to evaluate the performance of current DNA methylation-based classification and recurrence prediction models in Ped/AYA patients with meningiomas and identify age-associated molecular differences. As part of this study, we analyzed 1,568 meningioma samples with DNA methylation and clinical data, including subsets with whole-exome and RNA sequencing. Patients were grouped into Ped/AYA (≤39 years, n = 213) and adult (&gt;39 years, n = 1,355) cohorts. We assessed classifier performance, performed subgroup-specific model retraining, and compared molecular profiles across age groups. Our results showed that molecular classification differed significantly between age groups, with Ped/AYA tumors less frequently belonging to the most aggressive Proliferative Molecular Group. The DNA methylation-based recurrence model performed well in adults (AUC = 0.83) but poorly in the Ped/AYA cohort (AUC = 0.57). However, retraining the model on only younger patients improved performance (AUC = 0.75). In addition, Ped/AYA tumors exhibited significantly fewer chromosomal alterations, including lower frequencies of 1p, 6q, and 14q loss (p&lt;0.05). Taken together, these findings indicate that predominantly adult-trained methylation models underperform in younger meningioma patients due to both biological divergence and exclusion from training datasets. Our findings underscore the need for age-specific molecular tools to improve prognostication and support personalized care across the lifespan in neuro-oncology.
IMMU-91. Ligand receptor analyses of glioma immune microenvironment identifies Galectin-9 in microglia as regulator of tumor cell adhesion and phagocytosis
Gupta, Pravesh , Valdebenito-Silva, Silvana, Chakrapani, Prashanth, Oberai, Shivangi , Clise-Dwyer, Karen , Kumar, Gayatri , Dang, Minghao , Wang, Linghua , Eugenín, Eliseo A. , Bhat, Krishna

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v224-v224

10.1093/neuonc/noaf201.0889 Get It

Abstract Innate immune cells of macrophage family predominate tumor immune microenvironment of CNS malignancies. Although macrophages exhibit myriads of protective functions such as clearance of malignant cells, immune surveillance, inflammation resolution and tissue repair, they are generally linked to immunosuppression in gliomas. To identify anti-glioma myeloid cell effectors, we performed directionally concatenated ligand-receptor (L-R) interactome analyses from dendritic cells (DC) and microglia (MG) to lymphoid (CD4+T, Tregs, CD8+T, NK and NKT) cells identified by single cell transcriptomics analyses of ~145,000 tumor-associated CD45+ leukocytes from tumor brains of eighteen high-grade and low-grade glioma patients. Amongst DC-specific (e.g. adhesion molecules) and MG-specific (e.g. chemokine family) interactomes, we identified LGALS9 encoding Galectin-9 as the most pertinent interactions (e.g. SORL1 encoding sortilin-related receptor 1) in MG of IDH-wild type gliomas. Spectral cytometry, immunohistochemistry and western blotting analyses of MG, macrophage, DC, lymphoid cells and tumor cells confirmed abundant expression of Galectin-9 in glioma-associated MG and not in Nestin+ tumor cells. Furthermore, differential gene enrichment analyses revealed transcripts associated with cellular adhesion (coronin 1A, integrin) and phagocytosis (FcγR, phospholipase D, Rab family proteins etc.) was significantly upregulated in Galectin-9hi compared to Galectin-9lo/- MG and macrophages predicting putative role of Galectin-9 in tumor cell adhesion and phagocytosis. Using glioblastoma relevant patient derived ex vivo primary microglia (pMGs; 707, 2103, 1805) and glioma stem cell (GSC) co-culture model system, we evaluated the functional role of Galectin-9. Confocal imaging analyses of co-cultured pMGs with GSC revealed that siRNA or neutralizing antibody mediated downregulation of Galectin-9 led to significantly impaired adhesion (p&lt;0.001) between pMGs and GSC. Not only adhesion but even phagocytosis of GSC was dramatically attenuated (p&lt;0.0001) across all Galectin-9 silenced or neutralized pMGs. Altogether, our study underscores unappreciated role of Galectin-9 in MG as regulator of glioma cell adhesion and phagocytosis that can be harnessed for glioblastoma immunotherapy.
CSIG-31. REDEFINING THE GLIOBLASTOMA RESECTION MARGIN THROUGH SPATIAL CLONAL AND CELLULAR ECOSYSTEM ANALYSIS
Wang, Junlin , Lu, Xiaoling , Sereduk, Christopher, Hu, Leland , Tran, Nhan L. , Tran, Nhan L , Beniwal, Angad , Sereduk, Chris , Migliozzi, Simona , Garofano, Luciano , Plaisier, Christopher L. , Barajas, Ramon , Wang, Junwen

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v91-v91

10.1093/neuonc/noaf201.0365 Get It

Abstract Glioblastoma (GBM) invasion is shaped by dynamic clonal evolution within the spatial and cellular architecture of the brain. To investigate this process, we integrated multiparametric MRI, whole-exome sequencing (WES), bulk RNA-seq and single-nucleus RNA-seq (snRNA-seq) from 69 IDH-wildtype GBM patients, using spatially resolved biopsies from contrast-enhancing (CE) core tumor and non-enhancing (NE) invasive regions. Phylogenetic analysis revealed distinct clonal architectures. CE-enriched clones carried truncal mutations in conanical drivers of cell cycle and RTK signaling (TP53, PTEN, EGFR, PDGFRA/B), and private alterations in DNA repair genes (CDH11, PAX7, RAD51B). In contrast, NE-enriched clones exhibited private mutations in MAPK and Hippo pathways components (STAG2, BRAF, MAP2K3, CTNNA1), suggesting region-specific evolutionary trajectories. Furthermore, snRNAseq cell-cell communication analysis uncovered enriched ligand-receptor signaling in NE regions between malignant cells and brain-resident populations, including PTN—PTPRZ1 (myeloid), NRG-ERBB4 and SLIT-ROBO (neuronal, astrocytic, and oligodendrocytic). Bulk RNAseq deconvolution confirmed increased representation of neurons and glial cells in biopsies harboring NE-specific clones. These findings define a unique population of GBM clones localized at the infiltrative margin, marked by private MAPK/Hippo mutations and enhanced intracellular communication with the surrounding brain microenvironment. The recurrent engagement of neural-glial signaling pathways suggests that these NE-associated clones co-opt normal cellular networks to support invasion, immune evasion, and persistence following surgical resection. This study establishes a mechanistic link between spatial clonal evolution and tumor-host communication at the GBM infiltrative region and provide a framework for targeting cell-cell signaling circuits that sustain invasive tumor ecosystems and escape therapeutic treatment.
RADT-33. PROGNOSTIC AND PREDICTIVE EFFECT OF AGE IN MOLECULARLY-DEFINED LOWER GRADE GLIOMAS: A REPORT FROM THE PROSPECTIVE GLIOMA RESEARCH (PROGRES) DATABASE
Minniti, Giuseppe, Brown, Paul D. , Vogelbaum, Michael A., Mercurio, Ann, Siegelin, Markus D. , Touat, Mehdi, DeStephano, David, Shuryak, Igor , Roy, Soumyajit , Horowitz, David P. , Sisti, Michael B. , Bruce, Jeffrey N. , Canoll, Peter , Neugut, Alfred I. , Cheng, Simon K. , Kachnic, Lisa A. , Kinslow, Connor J , Kocakavuk, Emre , Tuohy, Kyle , Mansouri, Alireza , Touat, Mehdi , Ducray, François , Dehais, Caroline , Grinband, Jack , Yu, James , Walch, Henry , Parker, Mitchell I , Gallitto, Matthew , McKhann, Guy M. , Ostrom, Quinn T. , Pike, Luke R G , IWAMOTO, FABIO MASSAITI , Mehta, Minesh P. , Wang, Tony J. C.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v99-v100

10.1093/neuonc/noaf201.0403 Get It

Abstract PURPOSE Age over 40 years is commonly regarded as a “high risk” feature and potential indication for adjuvant chemoradiotherapy for patients with lower grade glioma in most clinical practice guidelines. However, these recommendations are based on retrospective observations and their subsequent incorporation into legacy clinical trials. It is unclear whether age remains a relevant prognostic factor in the molecular era. METHODS The Prospective Gliomas Research [PROGRES] Database contains individual patient-level data from 11 prospective clinical trials or observational registries, including seven international trials from the RTOG, EORTC, or Alliance cooperative groups. We determined the association of age with progression-free survival (PFS) in low grade or anaplastic glioma, stratified by isocitrate dehydrogenase (IDH1/2) status. We validated our findings in a separate multi-institutional retrospective cohort (Retrospective Glioma Research [REGRES] Database). RESULTS We identified 1,619 and 1,271 eligible patients in the PROGRES and REGRES cohorts, respectively. IDH-wildtype tumors were more common in patients &gt;40 years (38% vs, 5%, odds ratio: 11.3 [95%CI 6.5 – 19.7]). Age was associated with PFS in IDH-wildtype (5-year PFS: 6% vs, 24%, P =.003) but not in IDH-mutant glioma (60% vs, 59%, P = 0.22, P value of interaction &lt;.001). In IDH-wildtype tumors, older age predicted aggressive molecular features, including TERT promoter mutation (65% vs, 28%), EGFR amplification (41% vs, 15%), and chromosome +7/-10 alteration (57% vs, 25%). Age was not predictive of a benefit from chemoradiotherapy versus radiotherapy alone in IDH-mutant glioma. CONCLUSION Older age is a putative surrogate for IDH-wildtype status, but was not an independent predictor of progression in IDH-mutant lower grade glioma and did not predict benefit from chemoradiotherapy. In the absence of additional clinical or molecular risk factors, age alone should not be considered an indication for administration or deferral adjuvant treatment. Practice guidelines should be revised to reflect contemporary prognostic factors in the molecular era.